Science Explorer Back to mapMap
Discussion
Researcher · Rocky Mountain Cancer Centers · United States

Michael W. Meshad

Michael W. Meshad publishes mostly in Oncology, Pulmonary and Respiratory Medicine and Surgery, on topics such as Lung Cancer Treatments and Mutations, Cancer Treatment and Pharmacology and Cancer Genomics and Diagnostics.

OpenAlex
World rank
#2,050,710
of 7,710,434 ranked researchers
Rank in United States
#620,754
of 1,627,098
Works
19
Citations
2.3k
Citations per work
120.7
h-index
10
i10-index 11Top 59% in Oncology
Michael W. Meshad

What does Michael W. Meshad research?

Michael W. Meshad's work is mostly in Medicine (60%), Biochemistry, Genetics and Molecular Biology (18%).

Health Sciences: 11 works · 60.0% of their workMedicine: 11 works · 60.0% of their workOncology: 6 works · 32.7% of their workPulmonary and Respiratory Medicine: 3 works · 18.2% of their workSurgery: 2 works · 9.1% of their workEverything else: 4 works · 21.8% of their workLife Sciences: 3 works · 18.2% of their workBiochemistry, Genetics and Molecular Biology: 3 works · 18.2% of their workCancer Research: 1 works · 7.3% of their workMolecular Biology: 1 works · 7.3% of their workGenetics: 1 works · 3.6% of their workTHEIR WORKMichael W. Meshad19works
Life Sciences18%Health Sciences60%

Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.

The fields and subfields, with their numbers
    1. Medicine1160.0%
  2. Everything else421.8%
    1. Biochemistry, Genetics and Molecular Biology318.2%
  1. 1Oncology33% of their works
  2. 2Pulmonary and Respiratory Medicine18% of their works
  3. 3Surgery9% of their works
  4. 4Cancer Research7% of their works
  5. 5Molecular Biology7% of their works
  6. 6Genetics4% of their works

Research topics

Which keywords describe Michael W. Meshad's research?

The keywords of their largest research topics: Targeted Therapy, Clinical Trials, Chemotherapy, ALK Inhibitors, EGFR Mutations, Cetuximab, Chemotherapy-Induced Peripheral Neuropathy and Taxanes.

Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.

All 20 words, with their numbers
  1. Targeted Therapy123 topics
  2. Clinical Trials92 topics
  3. Chemotherapy83 topics
  4. ALK Inhibitors61 topic
  5. EGFR Mutations61 topic
  6. Cetuximab52 topics
  7. Chemotherapy-Induced Peripheral Neuropathy41 topic
  8. Taxanes41 topic
  9. Cancer Genomics31 topic
  10. Fluorouracil31 topic
  11. Genomic Profiles31 topic
  12. KRAS Mutations31 topic
  13. Mutational Signatures31 topic
  14. Postoperative Nausea31 topic
  15. Small-Cell Lung Cancer31 topic
  16. Vomiting Prevention31 topic
  17. Cancer Stem Cells21 topic
  18. Human Papillomavirus21 topic
  19. Oropharyngeal Cancer21 topic
  20. Tumor Metastasis21 topic

Where does Michael W. Meshad work?

Michael W. Meshad's main affiliation in the publication record is Rocky Mountain Cancer Centers, United States.

How many publications and citations does Michael W. Meshad have?

OpenAlex counts 19 works and 2,293 citations for Michael W. Meshad, an h-index of 10, ranking #2,050,710 of 7,710,434 researchers worldwide on the quality score.

Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.

Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.

Discussion

Ask a question or share a note about Michael W. Meshad. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.